[CAS NO. 1198151-75-5] Vapendavir diphosphate
PRODUCTS SPECIFICATIONS [1198151-75-5]
DESCRIPTION [1198151-75-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 578.45 |
| Molecular Formula | C21H32N4O11P2 |
| SMILES | CCOC1=NOC2=CC(OCCC3CCN(C4=CC=C(C)N=N4)CC3)=CC=C12.OP(O)(O)=O.OP(O)(O)=O |
1 Publications Citing Use of MCE
Summary
Vapendavir diphosphate (BTA798 diphosphate) is a potent enteroviral capsid binder (CB). Vapendavir diphosphate (BTA798 diphosphate) possesses potent antiviral activity for enterovirus 71 (EV71) replication, with EC 50 values of 0.5-1.4 μM in different EV71 strains [1] [2] .
In Vitro
Vapendavir (BTA798) efficiently inhibit the in vitro replication of 21 EV71 strains/isolates that are representative of the different genogroups A, B, and C [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03024177 | Vaxart |
Rhinovirus|Upper Respiratory Tract Infection
|
Phase 2 | |
| NCT02877264 | Aviragen Therapeutics|Vaxart |
Healthy
|
June 2016 | Phase 1 |
| NCT02367313 | Biota Pharmaceuticals, Inc.|Vaxart |
Asthma
|
February 2015 | Phase 2 |
| NCT02101866 | Biota Pharmaceuticals, Inc.|Vaxart |
Healthy
|
March 2014 | Phase 1 |
| NCT02204501 | Biota Scientific Management Pty Ltd|Vaxart |
Drug-Drug Interaction Healthy Volunteers
|
May 2014 | Phase 1 |
| NCT01175226 | Biota Scientific Management Pty Ltd|Vaxart |
Rhinovirus
|
August 2010 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 6.75 mg/mL ( 11.67 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7288 mL | 8.6438 mL | 17.2876 mL |
| 5 mM | 0.3458 mL | 1.7288 mL | 3.4575 mL |
| 10 mM | 0.1729 mL | 0.8644 mL | 1.7288 mL |
References
- [1] Tijsma A, et al. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob Agents Chemother. 2014 Nov;58(11):6990-2.
- [2] Sun L, et al. Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68. Antimicrob Agents Chemother. 2015 Dec;59(12):7782-5.